Innovation Through Partnership
We foster curiosity, embrace change, and champion technological innovation by empowering our team to challenge the status quo and seek to advance the boundaries of scientific scope, knowledge, and discovery. Our commitment to helping you get better treatments to patients faster includes building relationships with innovative technology providers to ensure the best cutting-edge research services remain at your fingertips.
Explore some of our current partnerships and collaborations below:
Virtual Control Groups (VCGs)
- Digital human models of disease developed with the help of AI
- Virtual control groups (VCGs), which allow for in silico pre-experiment workflows
- Helping to separate promising candidates from potential early failures
Machine Learning-Enabled Cryo-EM
- Structure determination for large and challenging structures
- Functional dynamic insight into targets, including candidate interaction and interference
- Rapid and accurate quantitative lipid nanoparticle characterization using statistically relevant sample populations
Human iPSC-Derived Cell Models
- Includes Alzheimer’s, Huntington’s, and ALS disease cells with matched controls, plus microglia and skeletal myocytes
- Generated via opti-ox™ precision reprogramming; engineered to contain disease mutations
- Enable screening, functional assays, and translational readouts in disease-relevant models
Custom Antibody Development
- Develop CHO clone pools of your 4-6 leads
- Assessment of formulation and manufacturability
- Material generation for late-stage in vitro and in vivo candidate selection studies and scale up to toxicology and GMP Phase 1 clinical supply
3D Tumor Model Screens
- 3D hydrogel tumor model panels to support your oncology and IO drug development
- 3D tumor models of PDX-derived cell lines and human dermal fibroblasts
- Targeted screening to determine therapeutic efficacy in an accurate model of the TME
Bioinformatics Services
- Sophisticated bioinformatics services to drive discovery and maximize ROI
- Leverage the complex data derived from today’s next-generation sequencing technologies
- Achieve accurate, robust, and in-depth analysis of big data
In Vivo Implantable Microdevice Technology
- A unique platform to boost oncology drug development projects
- In vivo testing of up to 18 different drugs, drug doses, or drug combinations in a single tumor
- Allows for multiple readouts, including multiplexed IHC and other advanced analytics
AI-Powered Drug Discovery
- Transforming targets into candidates using AI-powered drug-discovery processes
- Designed to add certainty and speed to your program with small molecule drug discovery expertise + AI
Charles River has a proud history of investing in and embracing innovations in biopharmaceutical research. With the adoption of digital technologies, the advent of artificial intelligence and advancements in science, we stand at the doorway to an exciting future where we can bring new treatments to patients as quickly and safely as possible."
Birgit Girshick, EVP, Chief Operating Officer
Recent Acquisitions
Charles River fosters collaborative working relationships with all partnerships. Here are some of our recent partnerships who formally joined the Charles River family through acquisition.
High-Throughput Mass Spec
- High-throughput screening campaigns without the limitation of optical interference leading to false-positive/negative results
- Agile assay design and rapid execution for label-free screening
- Detection of non-covalent binders in a site-agnostic manner with SAMDI ASMS
Cell Microarray Screening
- Screen for off-target binding against a comprehensive human protein library
- Discover novel, druggable targets, receptors targeted by phenotypic molecules, and disease-specific antigens
- Identification of cell surface receptors and immune checkpoint receptors